Tags

Type your tag names separated by a space and hit enter

Clinical and metabolic correction of pompe disease by enzyme therapy in acid maltase-deficient quail.
J Clin Invest. 1998 Feb 15; 101(4):827-33.JCI

Abstract

Pompe disease is a fatal genetic muscle disorder caused by a deficiency of acid alpha-glucosidase (GAA), a glycogen degrading lysosomal enzyme. GAA-deficient (AMD) Japanese quails exhibit progressive myopathy and cannot lift their wings, fly, or right themselves from the supine position (flip test). Six 4-wk-old acid maltase-deficient quails, with the clinical symptoms listed, were intravenously injected with 14 or 4.2 mg/kg of precursor form of recombinant human GAA or buffer alone every 2-3 d for 18 d (seven injections). On day 18, both high dose-treated birds (14 mg/kg) scored positive flip tests and flapped their wings, and one bird flew up more than 100 cm. GAA activity increased in most of the tissues examined. In heart and liver, glycogen levels dropped to normal and histopathology was normal. In pectoralis muscle, morphology was essentially normal, except for increased glycogen granules. In sharp contrast, sham-treated quail muscle had markedly increased glycogen granules, multi-vesicular autophagosomes, and inter- and intrafascicular fatty infiltrations. Low dose-treated birds (4.2 mg/kg) improved less biochemically and histopathologically than high dose birds, indicating a dose-dependent response. Additional experiment with intermediate doses and extended treatment (four birds, 5.7-9 mg/kg for 45 d) halted the progression of the disease. Our data is the first to show that an exogenous protein can target to muscle and produce muscle improvement. These data also suggest enzyme replacement with recombinant human GAA is a promising therapy for human Pompe disease.

Authors+Show Affiliations

Department of Animal Models for Human Disease, National Institute of Neuroscience, NCNP, Tokyo 187, Japan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

9466978

Citation

Kikuchi, T, et al. "Clinical and Metabolic Correction of Pompe Disease By Enzyme Therapy in Acid Maltase-deficient Quail." The Journal of Clinical Investigation, vol. 101, no. 4, 1998, pp. 827-33.
Kikuchi T, Yang HW, Pennybacker M, et al. Clinical and metabolic correction of pompe disease by enzyme therapy in acid maltase-deficient quail. J Clin Invest. 1998;101(4):827-33.
Kikuchi, T., Yang, H. W., Pennybacker, M., Ichihara, N., Mizutani, M., Van Hove, J. L., & Chen, Y. T. (1998). Clinical and metabolic correction of pompe disease by enzyme therapy in acid maltase-deficient quail. The Journal of Clinical Investigation, 101(4), 827-33.
Kikuchi T, et al. Clinical and Metabolic Correction of Pompe Disease By Enzyme Therapy in Acid Maltase-deficient Quail. J Clin Invest. 1998 Feb 15;101(4):827-33. PubMed PMID: 9466978.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Clinical and metabolic correction of pompe disease by enzyme therapy in acid maltase-deficient quail. AU - Kikuchi,T, AU - Yang,H W, AU - Pennybacker,M, AU - Ichihara,N, AU - Mizutani,M, AU - Van Hove,J L, AU - Chen,Y T, PY - 1998/3/21/pubmed PY - 1998/3/21/medline PY - 1998/3/21/entrez SP - 827 EP - 33 JF - The Journal of clinical investigation JO - J. Clin. Invest. VL - 101 IS - 4 N2 - Pompe disease is a fatal genetic muscle disorder caused by a deficiency of acid alpha-glucosidase (GAA), a glycogen degrading lysosomal enzyme. GAA-deficient (AMD) Japanese quails exhibit progressive myopathy and cannot lift their wings, fly, or right themselves from the supine position (flip test). Six 4-wk-old acid maltase-deficient quails, with the clinical symptoms listed, were intravenously injected with 14 or 4.2 mg/kg of precursor form of recombinant human GAA or buffer alone every 2-3 d for 18 d (seven injections). On day 18, both high dose-treated birds (14 mg/kg) scored positive flip tests and flapped their wings, and one bird flew up more than 100 cm. GAA activity increased in most of the tissues examined. In heart and liver, glycogen levels dropped to normal and histopathology was normal. In pectoralis muscle, morphology was essentially normal, except for increased glycogen granules. In sharp contrast, sham-treated quail muscle had markedly increased glycogen granules, multi-vesicular autophagosomes, and inter- and intrafascicular fatty infiltrations. Low dose-treated birds (4.2 mg/kg) improved less biochemically and histopathologically than high dose birds, indicating a dose-dependent response. Additional experiment with intermediate doses and extended treatment (four birds, 5.7-9 mg/kg for 45 d) halted the progression of the disease. Our data is the first to show that an exogenous protein can target to muscle and produce muscle improvement. These data also suggest enzyme replacement with recombinant human GAA is a promising therapy for human Pompe disease. SN - 0021-9738 UR - https://www.unboundmedicine.com/medline/citation/9466978/Clinical_and_metabolic_correction_of_pompe_disease_by_enzyme_therapy_in_acid_maltase_deficient_quail_ L2 - https://doi.org/10.1172/JCI1722 DB - PRIME DP - Unbound Medicine ER -